Opinion|Videos|July 9, 2024
Interchangeability Impacting Biosimilar Uptake
The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Has interchangeability impacted biosimilar adoption? If not, why?
- What value do switching studies bring to interchangeable biosimilars?
- Does this data matter more than the designation?
- Do pharmacies and providers value interchangeability?
- Have pharmacies begun acting upon interchangeability with automatic substitutions?
- What value do switching studies bring to interchangeable biosimilars?
Advertisement
Related to this article
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
4
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
5